Omidenepag isopropyl

异丙基奥米奈帕

Report date: 2025/03/26 20:01:25
NMEFirst In Class

Base Information

Drug NameOmidenepag isopropyl
Drug Alias Name异丙基奥米帕格EybelisOmlontiDE-117G0G0H52U6K +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid EP2 receptor agonists
TargetsProstanoid EP2 receptor
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Global Approved IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2018/09/21
Country/TerritoryUnited StatesSingaporeMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesUbe Industries LtdSanten
China Registration ClassN/A

Develop Information

Active CompaniesOcuvex Therapeutics IncVisiox Pharmaceuticals IncVisiox Pharma LLC +[7] 
Inactive CompaniesSanten Inc
Active IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeS01EX06
Related LinksKEGG